(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Live Chart Being Loaded With Signals
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases...
Stats | |
---|---|
今日成交量 | 15 499.00 |
平均成交量 | 40 793.00 |
市值 | 172.82M |
EPS | $0 ( 2024-04-03 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.270 |
ATR14 | $0.0520 (1.58%) |
Inventiva S.A. 财务报表
Annual | 2023 |
营收: | $17.48M |
毛利润: | $17.50M (100.13 %) |
EPS: | $-2.43 |
FY | 2023 |
营收: | $17.48M |
毛利润: | $17.50M (100.13 %) |
EPS: | $-2.43 |
FY | 2022 |
营收: | $12.18M |
毛利润: | $11.18M (91.83 %) |
EPS: | $-1.310 |
FY | 2021 |
营收: | $4.19M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.270 |
Financial Reports:
Symbol | Period | Year | Title |
---|---|---|---|
IVA | FY | 2023 | Inventiva S.A. Reports Fiscal Year 2023 Financial Results |
Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。